Given the multiple mechanisms of resistance to immunotherapy in prostate cancer, rational immuno-oncology combination strategies that activate both innate and adaptive immunity in prostate cancer, with a focus of on activation of c-GAS/STING signaling within the tumor microenvironment, carries the potential to enhance therapeutic efficacy. The gene discussed is CGAS; the disease is prostate cancer.